Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 18,378 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92. Following the completion of the transaction, the director directly owned 2,453,919 shares of the company’s stock, valued at approximately $1,570,508.16. This trade represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total value of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.

Werewolf Therapeutics Price Performance

NASDAQ HOWL traded down $0.00 on Wednesday, hitting $0.64. The stock had a trading volume of 208,688 shares, compared to its average volume of 310,372. The firm has a 50-day moving average of $0.94 and a 200-day moving average of $1.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 52-week low of $0.56 and a 52-week high of $2.38. The company has a market capitalization of $31.13 million, a price-to-earnings ratio of -0.40 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

HOWL has been the subject of a number of research reports. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. HC Wainwright cut their price target on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Citizens Jmp downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Bank of America cut their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at approximately $92,000. Vanguard Group Inc. raised its position in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the period. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics in the third quarter worth $304,000. 64.84% of the stock is owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.